EP1120113A2 - Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues - Google Patents
Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues Download PDFInfo
- Publication number
- EP1120113A2 EP1120113A2 EP01103552A EP01103552A EP1120113A2 EP 1120113 A2 EP1120113 A2 EP 1120113A2 EP 01103552 A EP01103552 A EP 01103552A EP 01103552 A EP01103552 A EP 01103552A EP 1120113 A2 EP1120113 A2 EP 1120113A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- steroid
- rar
- ligand
- hormone
- selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 57
- 201000010099 disease Diseases 0.000 title claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 42
- 239000005556 hormone Substances 0.000 title claims abstract description 35
- 229940088597 hormone Drugs 0.000 title claims abstract description 35
- 230000003637 steroidlike Effects 0.000 title claims abstract description 28
- 150000003431 steroids Chemical class 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 16
- 102000005962 receptors Human genes 0.000 claims description 38
- 108020003175 receptors Proteins 0.000 claims description 38
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims description 36
- 108091008726 retinoic acid receptors α Proteins 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 28
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 claims description 25
- 108091008760 retinoic acid receptors γ Proteins 0.000 claims description 25
- 102100033909 Retinoic acid receptor beta Human genes 0.000 claims description 23
- 108091008761 retinoic acid receptors β Proteins 0.000 claims description 23
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 claims description 22
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 13
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 12
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 12
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 12
- 229960001727 tretinoin Drugs 0.000 claims description 12
- -1 phenyl-naphthyl Chemical class 0.000 claims description 10
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 8
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 8
- 230000005945 translocation Effects 0.000 claims description 8
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 7
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 7
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 150000008366 benzophenones Chemical class 0.000 claims description 4
- 150000004492 retinoid derivatives Chemical group 0.000 claims description 4
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 claims description 3
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 claims description 3
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 claims description 3
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 claims description 3
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims description 2
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 108091008763 thyroid hormone receptors α Proteins 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 231100000673 dose–response relationship Toxicity 0.000 description 16
- 230000004044 response Effects 0.000 description 10
- 230000037361 pathway Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003094 perturbing effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108091008039 hormone receptors Proteins 0.000 description 3
- 102000027483 retinoid hormone receptors Human genes 0.000 description 3
- 108091008679 retinoid hormone receptors Proteins 0.000 description 3
- 102000027478 retinoid receptor subtypes Human genes 0.000 description 3
- 108091008678 retinoid receptor subtypes Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 108010066463 Retinoid X Receptor alpha Proteins 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical class C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000009835 non selective interaction Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the present invention relates to therapeutic uses of compounds which function as steroid hormones or steroid-like hormones.
- the present invention relates to the use of compounds which selectively or preferentially interact with a single subtype of a given steroid hormone or steroid-like hormone receptor class.
- chromosomal translocation e.g., a chromosomal translocation.
- PML for "promyelocytes”
- RAR- ⁇ retinoic acid receptor- ⁇
- APL acute promyelocytic leukemia
- a gene product not normally subject to hormone expression control e.g., PML
- a hormone responsive sequence e.g., RAR- ⁇
- a gene such as PML may fall under the control of a hormone responsive sequence (such as RAR- ⁇ ) as a result of a translocation event.
- APL can be effectively controlled by treatment with retinoic acid.
- retinoic acid e.g., RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , RXR- ⁇ , RXR- ⁇ , RXR- ⁇
- administration of retinoic acid as a treatment for APL has the potential to cause many undesirable side-reactions for the patient.
- Vitamin D-dependent Ricketts is responsive to treatment with Vitamin D
- acne is responsive to treatment with retinoic acid, and the like.
- available hormone or hormone-like compounds are effective for the treatment of such disease states, there is always the competing concern of undesirable side effects of such hormone treatments.
- Such compounds are useful for the selective treatment of hormone responsive disease states, thereby minimizing the occurrence of side effects caused by the activation of hormone responsive pathways not directly associated with the disease state being treated.
- Figure 1 is a dose response curve showing the response of RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ to increasing concentrations of retinoic acid.
- Figure 2 is a dose response curve showing the response of RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ to increasing concentrations of the phenyl-naphthyl derivative referred to herein as Compound I.
- Figure 3 is a dose response curve showing the response of RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ to increasing concentrations of the polyunsaturated carboxylic acid derivative referred to herein as Compound II.
- Figure 4 is a dose response curve showing the response of RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ to increasing concentrations of the amide derivative referred to herein as Compound III.
- Figure 5 is a dose response curve showing the response of RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ to increasing concentrations of the benzophenone derivative referred to herein as Compound IV.
- methods for the treatment of a subject afflicted with a steroid or steroid-like hormone-responsive disease state comprising administering to said subject an effective amount of a ligand which selectively interacts with the steroid or steroid-like hormone receptor subtype associated with said steroid or steroid-like hormone-responsive disease state, wherein said ligand selectively interacts with said steroid or steroid-like hormone receptor subtype associated with said steroid or steroid-like hormone-responsive disease state, to a significantly greater extent than do other subtypes of the same receptor class.
- steroid or steroid-like hormone-responsive disease state refers to:
- the phrase "ligand which selectively interacts with the receptor subtype associated with said steroid or steroid-like hormone responsive disease state to a significantly greater extent than with other subtypes of the same receptor class” refers to compounds which are preferentially selective for one receptor subtype in modulating the transcription activation properties thereof.
- the terminology "significantly greater extent”, as applied to interaction between ligand and a specific receptor subtype, refers to ligands which have a significantly higher therapeutic index (i.e., the ratio of efficacy to toxicity) for treatment of the target disease state than for activation of pathways mediated by other subtypes of the same receptor class.
- the present invention provides a means to dramatically reduce the incidence of side-reactions commonly associated with hormone therapy. See, for example, the selectivity demonstrated in Figures 2-5.
- receptors subtype and receptor "class”.
- retinoid responsive receptors comprise a "class” of receptors, all of which are responsive to retinoid compounds.
- thyroid hormone receptors comprise a "class” of receptors which are responsive to thyroid hormone.
- Each class can be divided into various subtypes, i.e., specific members of the class which have different tissue distributions, different affinities for the native ligand, different activation properties when contacted with the native ligand, and so on.
- Some classes of receptors include sub-families of distinctly different types of receptors.
- the retinoid class of receptors includes both the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), these two different sub-families are clearly distinct.
- each member of the RAR sub-family is responsive to a defined first hormone response element (HRE)
- each member of the RXR sub-family is responsive to a defined second HRE (which is distinctly different from the first HRE).
- Ligands contemplated by the present invention are selected from RAR- ⁇ selective ligands, RAR- ⁇ selective ligands, RAR- ⁇ selective ligands, TR- ⁇ -selective ligands, TR- ⁇ -selective ligands, RXR- ⁇ selective ligands, RXR- ⁇ selective ligands, RXR- ⁇ selective ligands, coup- ⁇ selective ligands, coup- ⁇ selective ligands, coup- ⁇ selective ligands, coup- ⁇ selective ligands, coup- ⁇ selective ligands, and the like.
- Exemplary selective ligands contemplated for use in the practice of the present invention include the phenyl-naphthyl derivative having the structure: referred to herein as Compound I, which selectively interacts with the retinoic acid receptor- ⁇ and retinoic acid receptor- ⁇ (see, for example, FIG. 2); the polyunsaturated carboxylic acid derivative having the structure: referred to herein as Compound II, which selectively interacts with RAR subtypes relative to RXR subtypes (see, for example, FIG.
- the amide having the structure: referred to herein as Compound III which selectively interacts with RAR- ⁇ , and displays a different rank order of potency relative to the other RAR subtypes and RXR- ⁇ , relative to the other retinoid compounds tested (see, for example, FIG. 4); the benzophenone derivative having the structure: referred to herein as Compound IV, which selectively interacts with the retinoic acid receptor- ⁇ and retinoic acid receptor- ⁇ (see, for example, FIG. 5), and the like.
- ligands in suitable form (employing suitable vehicle for delivery, such as, for example, gelatin capsule(s) or compressed tablet(s) where oral administration is contemplated; in an appropriate base where topical administration is contemplated; in a suitable infusion medium where injection or other means of delivery are contemplated; and the like), can be administered to a subject employing standard methods, such as, for example, orally, topically (e.g., transdermal mode of administration), by intraperitoneal, intramuscular, intravenous, or subcutaneous injection or implant, and the like.
- suitable vehicle for delivery such as, for example, gelatin capsule(s) or compressed tablet(s) where oral administration is contemplated; in an appropriate base where topical administration is contemplated; in a suitable infusion medium where injection or other means of delivery are contemplated; and the like
- suitable vehicle for delivery such as, for example, gelatin capsule(s) or compressed tablet(s) where oral administration is contemplated; in an appropriate base where topical administration is contemplated; in
- dosages in the range of about 1 up to 500 mg/kg body weight per day, depending on the disease state being treated, will be employed.
- Active compound can be administered in a sustained release form, or in divided doses throughout the day.
- topical delivery in the range of about 0.05 mg up to 10 mg/kg body weight per day, depending on the disease state being treated, will be employed.
- injection modes of delivery in the range of about 10 ⁇ g up to 2 mg/kg body weight per day, depending on the disease state being treated. It should be emphasized, however, that dosage requirements are variable and are typically individualized on the basis of the disease under treatment and the response of the patient.
- the proper maintenance dosage can be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest drug dosage which will maintain an adequate clinical response is reached.
- a method for the treatment of a subject afflicted with acute promyelocytic leukemia comprising administering to said subject an effective amount of a ligand which selectively interacts with retinoic acid receptors, in preference to retinoid X receptors.
- an effective amount of a ligand which selectively interacts with RAR- ⁇ , relative to other retinoic acid receptor subtypes (as well as retinoid X receptors) will be employed.
- physicians will determine the particular dosage of the selective ligand which is most suitable. The selected dosage will vary depending upon the mode of administration employed, the particular compound administered, the patient under treatment, and the particular disease being treated.
- the method of the invention can be applied to the selective treatment of skin disorders such as acne, psoriasis, photodamage, and the like.
- skin disorders such as acne, psoriasis, photodamage, and the like.
- compounds which selectively interact with RAR- ⁇ , relative to other retinoid receptors are preferred.
- a series of dose response curves were generated to determine the response of retinoic acid receptor- ⁇ , retinoic acid receptor- ⁇ , retinoic acid receptor- ⁇ and retinoid X receptor- ⁇ upon exposure to retinoic acid, Compound I (i.e., the phenyl-naphthyl derivative), Compound II (i.e., the polyunsaturated carboxylic acid derivative), and Compound III (i.e., the amide derivative), and Compound IV (i.e., the benzophenone derivative).
- Compound I i.e., the phenyl-naphthyl derivative
- Compound II i.e., the polyunsaturated carboxylic acid derivative
- Compound III i.e., the amide derivative
- Compound IV i.e., the benzophenone derivative
- retinoic acid receptor- ⁇ was encoded by vector pRShRAR-alpha (see US Patent No. 4,981,784, issued January 1, 1991, the entire contents of which are hereby incorporated by reference herein), retinoic acid receptor- ⁇ was encoded by vector pRShRAR-beta (see Brand et al. in Nature 332 :850 (1988) and Benbrook et al.
- retinoic acid receptor- ⁇ was encoded by vector pRShRAR-gamma (see USSN 370,407, filed June 22, 1989, the entire contents of which are hereby incorporated by reference herein), and retinoid X receptor- ⁇ was encoded by vector pRShRXR-alpha (see USSN 478,071, filed February 9, 1990, the entire contents of which are hereby incorporated by reference herein).
- the reporter vector used in all experiments was TREp- ⁇ MTV-LUC, as described by Umesono et al. in Nature 336 :262 (1988), the entire contents of which are hereby incorporated by reference herein.
- Figure 1 presents the results of a dose response study carried out with retinoic acid as the ligand for each of the receptors: RAR- ⁇ , PAR- ⁇ , RAR- ⁇ , and RXR- ⁇ .
- each of the retinoid receptor subtypes is activated to approximately the same extent.
- concentrations below about 1x10 -9 each of the retinoid receptor subtypes is activated to approximately the same extent.
- concentrations above about 1x10 -6 each of the retinoid receptor subtypes is activated to approximately the same extent.
- rank order potency as follows: RAR- ⁇ > RAR- ⁇ > RAR- ⁇ > RXR- ⁇ , retinoic acid is seen to exert a substantial effect on each of the retinoid receptors tested.
- Administration of retinoic acid as a therapeutic agent is, therefore, likely to induce many hormone mediated pathways, not just the pathway involved in the disease state to be treated.
- Figure 2 presents the results of a dose response study carried out with Compound I (phenyl-naphthyl derivative) as the ligand for each of the receptors: RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ .
- Compound I phenyl-naphthyl derivative
- each of the retinoid receptor subtypes is activated to approximately the same extent.
- concentrations above about 1x10 -8 there is a readily discerned rank order potency as follows: RAR- ⁇ ⁇ RAR- ⁇ >>> RAR- ⁇ ⁇ RXR- ⁇ .
- Compound I could be used for the treatment' of a disease state which involves RAR- ⁇ and/or PAR- ⁇ , without perturbing pathways which are responsive to RAR- ⁇ or the retinoid X receptor.
- Figure 3 presents the results of a dose response study carried out with Compound II (polyunsaturated carboxylic acid derivative) as the ligand for each of the receptors: RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ .
- Compound II polyunsaturated carboxylic acid derivative
- each of the receptor subtypes is activated to approximately the same extent.
- the rank order potency is as follows: RAR- ⁇ ⁇ RAR- ⁇ ⁇ RAR- ⁇ >> RXR- ⁇ .
- Compound II could be used for the treatment of a disease state which involves a retinoic acid receptor, without perturbing pathways which are responsive to the retinoid X receptor.
- Figure 4 presents the results of a dose response study carried out with Compound III (amide derivative) as the ligand for each of the receptors: RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ .
- each of the receptor subtypes is activated to approximately the same extent.
- concentrations below about 1x10 -9 each of the receptor subtypes is activated to approximately the same extent.
- concentrations above about 1x10 -7 each of the receptor subtypes is activated to approximately the same extent.
- concentrations between about 1x10 -9 and 1x10 -7 the rank order potency is as follows: RAR- ⁇ > RAR- ⁇ ⁇ RXR- ⁇ > RAR- ⁇ .
- Compound III could be used for the treatment of a disease state which involves RAR- ⁇ , while perturbing pathways which are responsive to other retinoid receptors to a much lesser extent.
- Figure 5 presents the results of a dose response study carried out with compound IV (benzophenone derivative) as the ligand for each of the receptors: RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , and RXR- ⁇ .
- each of the receptor subtypes is activated to approximately the same extent.
- concentrations above about 1x10 -8 there is a readily discernible rank order potency as follows: RAR- ⁇ ⁇ RAR- ⁇ >>> RAR- ⁇ ⁇ RXR- ⁇ .
- Compound IV could be used for the treatment of a disease state which involves RAR- ⁇ and/or RAR- ⁇ , without perturbing pathways which are responsive to RAR- ⁇ or the retinoid X receptor.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74876791A | 1991-08-23 | 1991-08-23 | |
US748767 | 1991-08-23 | ||
EP92919124A EP0600028B1 (fr) | 1991-08-23 | 1992-08-21 | Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92919124A Division EP0600028B1 (fr) | 1991-08-23 | 1992-08-21 | Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1120113A2 true EP1120113A2 (fr) | 2001-08-01 |
EP1120113A3 EP1120113A3 (fr) | 2003-05-07 |
Family
ID=25010830
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01103552A Ceased EP1120113A3 (fr) | 1991-08-23 | 1992-08-21 | Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues |
EP92919124A Expired - Lifetime EP0600028B1 (fr) | 1991-08-23 | 1992-08-21 | Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92919124A Expired - Lifetime EP0600028B1 (fr) | 1991-08-23 | 1992-08-21 | Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues |
Country Status (8)
Country | Link |
---|---|
US (1) | US6096787A (fr) |
EP (2) | EP1120113A3 (fr) |
JP (1) | JPH07505607A (fr) |
AT (1) | ATE208194T1 (fr) |
AU (1) | AU2516092A (fr) |
CA (1) | CA2114936C (fr) |
DE (1) | DE69232188T2 (fr) |
WO (1) | WO1993003713A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722985B1 (fr) * | 1994-07-27 | 1996-09-13 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations |
FR2723315B1 (fr) * | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
US5807900A (en) * | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
US5624957A (en) * | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
DK0873295T3 (da) | 1995-10-06 | 2003-07-14 | Ligand Pharm Inc | Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse |
US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
FR2802808B1 (fr) * | 1999-12-22 | 2002-08-09 | Oreal | Utilisation de composes polycycliques aromatiques en tant qu'activateurs des recepteurs de type ppars dans une composition cosmetique ou pharmaceutique |
US20040033600A1 (en) * | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
US8105825B2 (en) * | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
AU2002247184B2 (en) | 2001-02-20 | 2008-06-19 | Intrexon Corporation | Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system |
EP1534738B1 (fr) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Nouveaux recepteurs a mutant de substitution et utilisation de ceux-ci dans un systeme d'expression de gene inductible fonde sur un recepteur nucleaire |
JP4955905B2 (ja) * | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | キメラレチノイドx受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用 |
ES2422303T3 (es) | 2001-02-20 | 2013-09-10 | Intrexon Corp | Receptores mutantes por sustitución novedosos y su uso en un sistema de expresión génica inducible basado en receptores nucleares |
US7177763B2 (en) * | 2001-09-25 | 2007-02-13 | Werner Keber | Method and device for preventing unpermitted approach of airplanes to objects on the ground which are to be protected |
CA2820144C (fr) * | 2001-09-26 | 2017-06-20 | Intrexon Corporation | Acides nucleiques du recepteur a l'ecdysone de la cicadelle, polypeptides, et utilisation de ceux-ci |
CA2459807C (fr) | 2001-09-26 | 2013-09-03 | Jianzhong Zhang | Acides nucleiques, polypeptides du recepteur de l'ecdysone des aleyrodidae et utilisations ces derniers |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
BRPI0919348A2 (pt) | 2008-09-22 | 2015-12-29 | Kagosima University | fármaco terapêutico para leucemia da célula t adulta. |
JP6379173B2 (ja) | 2013-03-15 | 2018-08-22 | イントレキソン コーポレーション | ホウ素含有ジアシルヒドラジン |
US9944659B2 (en) | 2014-09-17 | 2018-04-17 | Intrexon Corporation | Boron-containing diacylhydrazine compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0170105A2 (fr) * | 1984-07-07 | 1986-02-05 | Koichi Prof. Dr. Shudo | Dérivés de l'acide benzoique |
EP0220118A2 (fr) * | 1985-10-11 | 1987-04-29 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Dérivés bicycliques naphtaléniques, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire et en cosmétique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4981784A (en) * | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
-
1992
- 1992-08-21 WO PCT/US1992/007064 patent/WO1993003713A1/fr active IP Right Grant
- 1992-08-21 EP EP01103552A patent/EP1120113A3/fr not_active Ceased
- 1992-08-21 AU AU25160/92A patent/AU2516092A/en not_active Abandoned
- 1992-08-21 JP JP5504607A patent/JPH07505607A/ja active Pending
- 1992-08-21 EP EP92919124A patent/EP0600028B1/fr not_active Expired - Lifetime
- 1992-08-21 DE DE69232188T patent/DE69232188T2/de not_active Expired - Fee Related
- 1992-08-21 CA CA002114936A patent/CA2114936C/fr not_active Expired - Fee Related
- 1992-08-21 AT AT92919124T patent/ATE208194T1/de active
-
1997
- 1997-09-16 US US08/931,694 patent/US6096787A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0170105A2 (fr) * | 1984-07-07 | 1986-02-05 | Koichi Prof. Dr. Shudo | Dérivés de l'acide benzoique |
EP0220118A2 (fr) * | 1985-10-11 | 1987-04-29 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Dérivés bicycliques naphtaléniques, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire et en cosmétique |
Non-Patent Citations (9)
Title |
---|
A. KAKIZUKA ET AL.: "Molecular cloning and characterization of aberrant retinoic acid receptors from a t(15;17) positive acute promyelocytic leukemia patient" JOURNAL OF CELLULAR BIOCHEMISTRY, vol. suppl., no. 15G, April 1991 (1991-04), page 31 XP008014847 * |
ASTROM A ET AL: "RETINOIC ACID AND SYNTHETIC ANALOGS DIFFERENTIALLY ACTIVATE RETINOIC ACID RECEPTOR DEPENDENT TRANSCRIPTION" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 173, no. 1, 30 November 1990 (1990-11-30), pages 339-345, XP000570308 ISSN: 0006-291X * |
CRETTAZ M ET AL: "LIGAND SPECIFICITIES OF RECOMBINANT RETINOIC ACID RECEPTORS RARALPHA AND RARBETA" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 272, no. 2, 1 December 1990 (1990-12-01), pages 391-397, XP000576614 ISSN: 0264-6021 * |
DELESCLUSE C ET AL: "SELECTIVE HIGH AFFINITY RETINOIC ACID RECEPTOR ALPHA OR BETA-Y LIGANDS" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 40, no. 4, 1 October 1991 (1991-10-01), pages 556-562, XP000576255 ISSN: 0026-895X * |
FREY J R ET AL: "ANTIPROLIFERATIVE ACTIVITY OF RETINOIDS, INTERFERON ALPHA AND THEIRCOMBINATION IN FIVE HUMAN TRANSFORMED CELL LINES" CANCER LETTERS, NEW YORK, NY, US, vol. 57, no. 3, 1991, pages 223-227, XP001063973 ISSN: 0304-3835 * |
GRAUPNER G ET AL: "6'-SUBSTITUTED NAPHTHALENE-2-CARBOXYLIC ACID ANALOGS, A NEW CLASS OF RETINOIC ACID RECEPTOR SUBTYPE-SPECIFIC LIGANDS" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 179, no. 3, 30 September 1991 (1991-09-30), pages 1554-1561, XP000575991 ISSN: 0006-291X * |
J.E.F. REYNOLDS: "MARTINDALE THE EXTRA PHARMACOPOIEA" 1989 , THE PHARMACEUTICAL PRESS , LONDON XP002234601 Acitretin * page 916 * * |
KAGECHIKA H ET AL: "DIFFERENTIATION INDUCERS OF HUMAN PROMYELOCYTIC LEUKEMIA CELLS HL-60. PHENYLCARBAMOYLBENZOIC ACIDS AND POLYENE AMIDES" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 34, no. 5, 1 May 1986 (1986-05-01), pages 2275-2278, XP000653341 ISSN: 0009-2363 * |
LEHMANN J M ET AL: "IDENTIFICATION OF RETINOIDS WITH NUCLEAR RECEPTOR SUBTYPE-SELECTIVEACTIVITIES" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 51, 15 September 1991 (1991-09-15), pages 4804-4809, XP000576285 ISSN: 0008-5472 * |
Also Published As
Publication number | Publication date |
---|---|
DE69232188T2 (de) | 2002-06-20 |
WO1993003713A1 (fr) | 1993-03-04 |
JPH07505607A (ja) | 1995-06-22 |
EP0600028A1 (fr) | 1994-06-08 |
EP0600028B1 (fr) | 2001-11-07 |
CA2114936C (fr) | 2004-02-10 |
CA2114936A1 (fr) | 1993-03-04 |
DE69232188D1 (de) | 2001-12-13 |
EP1120113A3 (fr) | 2003-05-07 |
AU2516092A (en) | 1993-03-16 |
ATE208194T1 (de) | 2001-11-15 |
US6096787A (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1120113A2 (fr) | Emploi de ligands selectifs dans le traitement d'etats pathologiques sensibles aux hormones steroides ou analogues | |
US5668175A (en) | Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids | |
AU739440B2 (en) | Treatment of cell-mediated immune diseases | |
EP1602372B1 (fr) | Medicament ameliorant le pronostic de l'hemorragie sous arachnoidienne | |
US6133309A (en) | Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists | |
WO2021214545A1 (fr) | Formulations pharmaceutiques transdermiques et/ou topiques comprenant du cannabidiol et/ou du tétrahydrocannabinol pour le traitement de la douleur chronique | |
US20090203792A1 (en) | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | |
JP2002513389A (ja) | パーキンソン病を治療するための方法並びに装置 | |
JPH0672868A (ja) | 抗精神病薬 | |
EP1771166A2 (fr) | Traitement de maladies inflammatoires avec des antagonistes du rxr | |
Barat et al. | Cocaine and lidocaine in combination are synergistic convulsants | |
Adamson et al. | Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey | |
DiGiovanna | Retinoids for the future: oncology | |
Bacman et al. | Dapsone and retinoids | |
US20080090850A1 (en) | Herpetic neuralgia topical treatment | |
US8541469B2 (en) | Treatment of cell-mediated immune diseases | |
KULKARNI et al. | Diclofenac and enolicam as ocular anti-inflammatory drugs in rabbit corneal wound model | |
JPH06172165A (ja) | 炎症性皮膚疾患治療用外用剤 | |
Cope et al. | Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention | |
EP1235580A2 (fr) | Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine | |
WO2006010504A1 (fr) | Traitement de la sclerose en plaques au moyen d'antagonistes de rxr | |
Anadkat et al. | 3 Systemic Retinoids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010219 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 600028 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STEIN, ROBERT B. Inventor name: BERGER, CHRISTINA S. Inventor name: HEYMAN, RICHARD A. Inventor name: EVANS, RONALD M. |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 20040421 |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APAI | Date of receipt of notice of appeal modified |
Free format text: ORIGINAL CODE: EPIDOSCNOA2E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20070329 |